NRG Oncology recently reported the results of the phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and ...

First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, ...

A clinical trial of an experimental cell therapy shows promising results for glioblastoma patients, with tumors disappearing ...

The tumor, which occurs when supportive cells in the brain grow and divide uncontrollably, is extremely aggressive and deadly. Most patients survive only 14 to 16 months after diagnosis.

NRG Oncology recently reported the results of the National Cancer Institute sponsored phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and nivolumab with radiation therapy (RT) ...

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

Man with deadly glioblastoma shows no signs of disease after taking experimental immunotherapy drug ipilimumab, inspiring a ...

Strong cash position of $12.1 million expected to fund operations into the second half of 2026Driving lead program, TPI 287, towards Phase 2 study for treatment of glioblastoma multiforme (GBM) ...

After decades of limited progress—owing to the difficulty of treating the disease and resultant market risk—glioblastoma ...

On the latest episode of "The Conversation," KSAT’s Stephania Jimenez spoke with a local doctor about glioblastoma and a ...

Linda Scelza knew what would happen when she told her son, Ryder, it was “OK to go.” Ryder Scelza took two more breaths and then died in his her arms, she said. He was 21. Ryder Scelza, of Rocky Hill, ...

NUAK2 was found to be re-expressed in glioblastoma and function as a fetal oncogene that promotes tumor growth and migration.